New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2014
08:14 EDTEPZMEpizyme announces publication of preclinical data for EPZ-6438
Epizyme announced the publication of data from preclinical studies of the company's clinical candidate EPZ-6438, a potent and selective small-molecule inhibitor of EZH2, a histone methyltransferase. Oncogenic mutations in EZH2 occur in a subset of patients with non-Hodgkin lymphoma, implicating EZH2 as a therapeutic target in these patients. Detailed characterization of the correlation between EZH2 inhibition, methylation of the EZH2 target (H3K27), reversal of lymphomagenic gene expression and antiproliferative effects specific to EZH2 mutant-bearing NHL cell lines. Sustained tumor growth inhibition in animal models of EZH2 mutant-bearing NHL, including durable effects after drug dosing is discontinued.
News For EPZM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
10:38 EDTEPZMEpizyme update for EPZ-6438 encouraging, says Mizuho
Subscribe for More Information
06:33 EDTEPZMEpizyme to host conference call
Conference call to discuss results from the Phase 1 dose escalation study of the investigational EZH2 inhibitor EPZ-6438 will be held on November 20 at 8 am. Webcast Link
November 19, 2014
18:06 EDTEPZMEpizyme reports results from Phase 1 dose study of EZH2 inhibitor EPZ-6438
Subscribe for More Information
November 18, 2014
07:20 EDTEPZMEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use